| Merkel cell carcinoma

Zynyz vs Bavencio

Side-by-side clinical, coverage, and cost comparison for merkel cell carcinoma.

Deep comparison between: Zynyz vs Bavencio with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBavencio has a higher rate of injection site reactions vs Zynyz based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Bavencio but not Zynyz, including UnitedHealthcare

Category

Zynyz

Bavencio

At A Glance

RouteIntravenous infusion

FrequencyEvery 3 or 4 weeks

ClassPD-1 blocking antibody

RouteIV infusion

FrequencyEvery 2 weeks

ClassPD-L1 blocking antibody

Indications

Primary squamous cell carcinoma of anal canal
Merkel cell carcinoma

Merkel cell carcinoma
Urothelial Carcinoma
Renal Cell Carcinoma

Dosing

Primary squamous cell carcinoma of anal canal (Combination therapy) 500 mg every 4 weeks or 375 mg every 3 weeks in combination with carboplatin and paclitaxel until disease progression, unacceptable toxicity, or up to 12 months

Primary squamous cell carcinoma of anal canal (Monotherapy, platinum-refractory) 500 mg every 4 weeks or 375 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months

Merkel cell carcinoma 500 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months

Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.

Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.

Contraindications

—

Drug Interactions

26View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=10%) with combination therapy Fatigue, peripheral neuropathy, nausea, alopecia, diarrhea, musculoskeletal pain, constipation, hemorrhage, rash, vomiting, decreased appetite, pruritus, abdominal pain

Most common (>=10%) with SCAC monotherapy Fatigue, musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite, constipation, abdominal pain, dyspnea, pyrexia, vomiting, cough, pruritus, hypothyroidism, headache, decreased weight

Most common (>=10%) in MCC Musculoskeletal pain, fatigue, pruritus, diarrhea, rash, pyrexia, nausea, constipation

Serious Sepsis, pulmonary embolism, diarrhea, vomiting, non-urinary tract infection, perineal pain, anemia, hemorrhage, arrhythmia, pneumonitis, immune-mediated adverse reactions

Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache

Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events

Postmarketing neutropenia, sclerosing cholangitis

Pharmacology

Retifanlimab-dlwr is a PD-1 blocking antibody that binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity to restore immune surveillance of tumors.

Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Zynyz